Anthony Davies has worked in the cell and gene therapy field for ∼20 years, at such companies as Onyx Pharmaceuticals and Geron. He is now president of Dark Horse Consulting. Nature Biotechnology spoke to Davies about the history of human embryonic stem cells in clinical trials, challenges in bringing future products to market and the overall prognosis for the field. http://www.nature.com/nbt/podcast/index.html.